TRIM72 and myocardial infarction: A series of studies has shown that recombinant human MG53 (rhMG53) protein protects various cell types against membrane disruption when applied to the extracellular environment and ameliorates pathology associated with muscular dystrophy [29], acute lung injury [30], myocardial infarction [31], acute kidney injury [32], and ischemic brain damage [33] in animal models.